Marstacimab for treating severe haemophilia A or severe haemophilia B in people 12 years and over [ID6342] Draft guidance Technology appraisal guidance 6 February 2025 Capivasertib with fulvestrant ...

NICE, in collaboration with other international health technology assessment agencies, has published a new report which ...

We use the best available evidence to develop recommendations that guide decisions in health, public health and social care.

We use the best available evidence to develop recommendations that guide decisions in health, public health and social care.

Healthy eating and weight management in pregnancy, and healthy eating in children up to 5 years: the care you should expect Eating well before, during and after pregnancy means that both mother and ...

This guideline covers the prevention and management of overweight, obesity and central adiposity in children, young people and adults. It brings together and updates all NICE's previous guidelines on ...

The 4 technology appraisal committees are standing advisory committees of NICE. This topic was considered by committee A. Committee members are asked to declare any interests in the perioperative ...

Durvalumab (Imfinzi, AstraZeneca) with platinum-based chemotherapy as neoadjuvant treatment, and then as monotherapy after surgery, is indicated for 'the treatment of adults with resectable (tumours ≥ ...

All NICE products on varicose veins. Includes any guidance and quality standards.

Critical assessment of evidence to help you make decisions. Advice, rather than formal NICE guidance.

NICE has developed tools and resources, in association with relevant stakeholders, to help organisations put this guidance into practice. The evidence generation plan gives further information on the ...

For further information on the guideline development process, please see how we develop NICE guidelines ...